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1. Introduction  
Opioid-induced bowel dysfunction (OIBD) is a collective term used to describe the 
gastrointestinal side effects of long-term opioid therapy in chronic pain patients.  
Constipation, nausea, vomiting, bloating, abdominal pain, and gastric reflux are among the 
most common gastrointestinal adverse effects. Within opioid-induced bowel dysfunction, a 
more specific subset exists, opioid-induced constipation, characterized by infrequent stools, 
straining, hard, dry stools, and incomplete evacuation. In these patients, the constipation 
can be so severe that they are willing to compromise their pain management by reducing 
their opioid analgesic dose, switch to a less potent opioid with inadequate pain relief, or 
completely discontinue their opioid medication all together. It is evident that opioid-
induced constipation remains a significant barrier to achieving optimal pain management 
and represents a large unmet medical NEED.  
Opioids induce gastrointestinal side effects indirectly through an effect on the central 
nervous system and directly through an effect on the gastrointestinal tract. Related to the 
indirect effect, it has been shown that intrathecal administration of opioids decreases 
gastrointestinal motility and intestinal secretion (Anderson, 2007). The direct effect is 
mediated through mu-opioid receptors in the neuronal plexi, located between the 
longitudinal and circular muscle layers (myenteric plexus) and within the submucosa 
(submucosal plexus). Within the myenteric plexus, the opioids induce relaxation of the 
longitudinal smooth-muscle layer and increase tonicity in the circular smooth-muscle layer. 
These effects are thought to be mediated through inhibition of acetylcholine release and 
inhibition of vasoactive intestinal peptide and nitric oxide release, respectively. The result of 
this differential effect on the longitudinal and circular intestinal smooth muscles is an 
increase in segmental contraction and a decrease in peristaltic activity.  
Normal peristalsis in the small bowel occurs every 90 minutes in order to move the luminal 
contents from the duodenum to the ileum.  Mass movements in the large bowel occurs less 
often, one to three times per day, sweeping its contents over longer distances.  As a result of 
the reduced peristalic activity, the transit time is significantly prolonged.  The food stays in 
the stomach longer and the stool resides in the small and large bowel. The former causes 
gastric distension, resulting in nausea and gastric reflux, and the latter contributes to the 
constipation by allowing more time for fluid absorption, a predominant function of the large 
bowel in particular. A decrease in bowel-movement frequency is the primary symptom of 
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constipation, with secondary symptoms being hard, dry stool, the need for straining with 
bowel movements, and a sense of incomplete evacuation. Tertiary symptoms are abdominal 
bloating/distension, discomfort, and pain from stool or gas, borborygmi, flatulence, and 
dyspnea from interference of the abdominal stool and gas content with diaphragmatic 
contraction aiding inspiration. Aside from these physiologic effects exuded by the opioid 
analgesics themselves, the lifestyle of patients in chronic pain typically intensifies their 
condition. Chronic pain patients are often inactive and deconditioned. They are more likely to 
be overweight, have a poor diet, and get little to no exercise, exacerbating their constipation.  
2. Prevalence  
In 2010, it was estimated that approximately 250 million prescriptions were written for 
opioids in the United States (IMS Health 2010) and many studies indicate that a high 
percentage of patients receiving opioids experience gastrointestinal side effects. A 
systematic review was performed of 11 randomized, double-blind, placebo-controlled 
studies of oral opioids in the treatment of chronic non-cancer pain, given for periods 
ranging from 4 days to 8 weeks (Kalso et al., 2004). The opioids were morphine in five 
studies, morphine or methadone in one study, and oxycodone in four studies; all studies 
used inactive placebo except two in which benztropine was given as active placebo. Of the 
1,025 subjects randomized, 674 subjects completed the study they were in and 698 subjects 
were evaluable. Adverse events and lack of efficacy were the most frequent reasons for 
discontinuation during both opioid and placebo treatment. The mean final daily doses of the 
oral opioids varied from 30 to 120 mg for morphine, 20 to 45 mg for oxycodone (30 to 68.5 
mg morphine equivalents), and 15 mg for methadone (45 mg morphine equivalents).  
Constipation was the most common adverse event in the opioid-treated subjects, reported by 
41% of the subjects in comparison to 11% of those treated with placebo, followed by nausea 
(32% versus 12%). The actual occurrence of constipation with oral opioid treatment in the range 
of 30 to 120 mg morphine equivalents per day is probably higher. The enriched nature of the 
studies excluded subjects from randomization who did not tolerate the medication or who did 
not find it effective in relieving their pain. The subjects who were not randomized because of 
the latter reason would also have discontinued the medication in practice; however, the 
subjects who were not randomized because of tolerability reasons would possibly have 
continued the treatment if the adverse event was constipation and this was effectively treated.  
3. Available treatments 
In 2008, the Food and Drug Administration approved a peripherally-acting mu-opioid-
receptor antagonist (PAMORA), subcutaneous methylnaltrexone (Relistor®), for the 
treatment of opioid-induced constipation in patients with advanced illness who are 
receiving palliative care when response to traditional laxative therapy has been inadequate. 
Another peripherally-acting mu-opioid-receptor antagonist, alvimopan, was being studied 
as well but cardiovascular safety concerns, consisting of an increased risk of myocardial 
infarction, halted drug development. However, the Food and Drug Administration 
approved the medication in 2008 with a Risk Evaluation and Mitigation Strategy (REMS) for 
the indication of accelerating the time to upper and lower gastrointestinal recovery, 
following partial small- or large-bowel resection with primary anastomosis. The Risk 
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Evaluation and Mitigation Strategy restricts the use of the medication to short-term (15 
doses) treatment in hospitalized patients and only in hospitals that have registered with the 
program and have met all the requirements.  
Lubiprostone and tegaserod are Food and Drug Administration approved for the treatment 
of chronic idiopathic constipation in adults and can, of course, be used off label for this 
condition as well. Lubiprostone is an activator of the CIC-2 chloride channel, increasing 
water secretion in the lumen of the gastrointestinal tract, and tegaserod is a non-selective 
serotonin-4-receptor agonist. However, in 2007, upon request from the Food and Drug 
Administration, alleging increased risk of cardiovascular and cerebrovascular events, 
Novartis withdrew tegaserod from the market. Prior to its withdrawal, tegaserod was being 
studied for opioid-induced constipation. A prokinetic medication could be used as well, 
although not approved by the Food and Drug Administration for (opioid-induced) 
constipation, such as cisapride, a non-selective serotonin-4-receptor agonist, domperidone, a 
peripherally-acting dopamine-receptor antagonist, or metoclopramide, a dopamine-2-
receptor antagonist and mixed serotonin-3-receptor antagonist/serotonin-4-receptor 
agonist. However, cisapride was withdrawn from the market because of long QT syndrome 
predisposing to arrhythmias, domperidone is not on the market in the United States, and the 
long-term, daily use of metoclopramide is not recommended because of potential 
extrapyramidal side effects, particularly tardive dyskinesia. Misoprostol, a synthetic 
prostaglandin E1 analogue, approved by the Food and Drug Administration for the 
prevention of gastric ulcers caused by the use of non-steroidal anti-inflammatory drugs 
(NSAIDs), also increases colonic transit and can be used off label as well.  
Another strategy that is used to treat opioid-induced constipation is to switch to an opioid 
that, in general, causes less constipation as a side effect. From a constipation perspective and 
according to our experience, morphine, codeine, and hydrocodone tend to be worse and, for 
example, oxycodone and fentanyl better. Opioids that produce analgesia through other 
mechanisms, such as tramadol and tapentadol, which apart from being mu-opioid-receptor 
agonists also inhibit the presynaptic uptake of noradrenaline, tend to cause less constipation.    
Over the counter constipation products in general can also be used for opioid-induced 
constipation, such as bulking agents (cellulose, psyllium), stool softeners (docusate), osmotic 
agents (lactulose, sorbitol, magnesium citrate, polyethylene glycol), and laxatives (senna, 
bisacodyl). Although traditional laxatives have proved efficacious at inducing bowel 
movments, they are a temporary, quick fix and frequently induce undesired side effects. For 
many patients a successful bowel movement requires a cumbersome combination of stool 
softeners, bowel stimulants, and osmotic agents. The unpredictable nature of stimulant 
laxatives are unappealing for patients as well. Aggressive laxative use does not come 
without the risk of serious side effects, including metabolic abnormalities, and the long term 
safety and relief of abdominal symptoms has yet to be revealed. One exception is Miralax 
(polyethylene glycol) which demonstrated sustained efficacy in long-term studies. 
Furthermore, traditional laxatives are not specifically approved by the Food and Drug 
Administration (FDA) for opioid-induced constipation.  
4. Drug development  
Given the paucity of FDA-approved medications and the sub-optimal efficacy of over the 
counter options for the treatment of opioid-induced constipation, a new drug class, 
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peripherally-acting mu-opioid receptor antagonists (PAMORAs), has evolved that directly 
targets the mechanism of opioid-induced constipation. The first two drugs to enter the 
market were subcutanous methylnaltrexone (Relistor®) in April 2008 and an oral 
formulation of alvimopan (Entereg®) in May 2008. However, both drugs were FDA-
approved in a specific sub-population, palliative care patients and post-surgical patients, 
respectively. Thus, the treatment for the general population with opioid-induced 
constipation reamined limited. Since 2008, several pharmaceutical companies have 
developed peripherally-acting mu-opioid receptor antagonists that are now undergoing 
various phases of clinical studies with the specific indication of opioid-induced constipation 
in chronic pain patients. 
Peripherally-acting mu opioid-receptor antagonists are an improvement to the traditional 
non-specific opioid-antagonists, naloxone and naltrexone. The novelty behind the new class 
resides with its restricted activity to the peripheral mu-opioid receptors in the enteric system 
and increased specificity to the mu-receptors versus the kappa- and delta-receptors. As a 
result, the constipating effects of opioids on gastrointestinal function and motility are 
inhibited without crossing the blood-brain barrier and reversing the central analgesic effects 
of opioids.   
Amoung the drugs currently being developed, the oral formulation is the most popular. 
While subcutaneous methylnaltrexone (Relistor) has already been approved by the Food 
and Drug Administration, clinical studies with the oral formulation are underway. Other 
oral, peripherally-acting mu-opioid receptor antagonists in development for opioid-induced 
constipation are ADL5945 (Adolor), ALKS37 (Alkermes), NKTR-118 (AstraZeneca), S-297995 
(Shionogi), and TD-1211 (Theravance). Lubiprostone, already FDA-approved for other types 
of constipation, is undergoing development for opioid-induced constipation as well. 
Medications that are in development for chronic constipation and may ultimately also be 
developed for opioid-induced constipation are the selective serotonin-4-receptor agonist, 
prucalopride (Johnson & Johnson), and the guanylate-cyclase C-receptor agonists, 
linaclotide (Ironwood) and plecanatide (Synergy).  
4.1 Methylnaltrexone 
Methylnaltrexone is a quaternary derivative of naltrexone, synthesized by adding a methyl 
group to the nitrogen atom of the molecule. Quaternary opioid antagonists are constructed to 
have more polarity and, therefore, less lipid solubility than their parent compounds. The 
reduced ability to penetrate the blood-brain barrier allows the medications to block opioid-
induced constipation peripherally, without antagonizing the centrally-mediated opioid 
analgesia or causing central opioid withdrawal. 
Methylnaltrexone was initially tested in an intravenous formulation. A laxation response 
was seen in 11 subjects with methadone-induced constipation who were treated with 
methylnaltrexone IV, compared to no laxation response in the 11 subjects in the placebo 
group (P<0.001)2. Along with the 100% response rate in the methylnaltrexone recipients, no 
central opioid withdrawal was observed and no significant adverse events were reported. 
At the same time, the oral-cecal transit time was decreased by 77.7 minutes from baseline in 
the methylnaltrexone group, while only by 1.4 minutes in the placebo group (p<0.001). 
Subsequently, subcutaneous administration was studied, potentially enlarging the target 
population for this treatment.  
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In a double-blind, randomized, placebo-controlled study in healthy volunteers, oral-cecal 
transit time was significantly reduced after 0.3 mg/kg subcutaneous methylnaltrexone plus 
morphine, compared with placebo plus morphine (P<0.05) ((Yuan et al, 2002). As an 
intervention for opioid-induced constipation in advanced illness, 0.15 mg/kg subcutaneous 
methylnaltrexone caused a laxation response within 4 hours in 48% of 62 subjects in the 
methylnaltrexone group, compared to 15% of the 71 subjects in the placebo group (p<0.001). 
Fifty two percent of the subjects had laxation without the use of a rescue laxative within 4 
hours after two or more of the first four doses, as compared to 8% in the placebo group 
(P<0.001) ((Thomas et al, 2008). The treatment did not affect centrally-mediated analgesia 
and did not precipitate opioid withdrawal. Abdominal pain and flatulence were the most 
common adverse events. 
A similar study in opioid-induced constipation in advanced illness used a single 
subcutaneous injection of methylnaltrexone, 0.15 mg/kg or 0.3 mg/kg, or placebo (Slatkin et 
al, 2009). Sixty two percent and 58% of the subjects treated with methylnaltrexone 0.15 
mg/kg and 0.3 mg/kg, respectively, had a laxation response within 4 hours, compared to 
14% of the subjects in the placebo group (P<0.0001; each dose versus placebo). Adverse 
events were slightly more common in the subjects treated with 0.15 mg/kg than in those 
treated with 0.3 mg/kg, particularly abdominal pain, flatulence, nausea, and dizziness. Due 
to a comparable efficacy profile, the results suggest the lower dose, 0.15 mg/kg, to be most 
optimal.  
Methylnaltrexone in a dose of 12 mg subcutaneous was given once daily or every other day 
for 28 days in a randomized, double-blind, placebo-controlled study, which involved a total 
of 469 subjects with opioid-induced constipation (Slatkin et al, 2009). Compared to placebo, 
the medication given once daily significantly improved rectal symptoms (P<0.05), stool 
symptoms (P<0.001), and global constipation scores (P<0.001), while given every other day 
significantly improved stool symptoms (P<0.05) and global constipation scores (P<0.05). The 
changes from baseline in abdominal symptoms and pain scores between the two 
methylnaltrexone groups and placebo were not significant.  
Although the intravenous and subcutaneous formulations produced promising results, they 
are impractical for the general population. An intravenous administration can only be 
administered under the supervision of health care professionals, and while the 
subcutaneous injections are more safe and convenient, they either require self-
administration or frequent assistance. An oral formulation is the most favorable as a pill is 
generally more convenient and affordable. Fortunately, phase 3 studies have commenced, 
assessing the safety and efficacy of oral methylnaltrexone for opioid-induced constipation in 
chronic pain patients.  
4.2 ADL5945 
ADL5945 is an oral peripherally-acting mu-opioid-receptor antagonist in development by 
Adolor with two randomized, double-blind, placebo-controlled studies recently completed 
in subjects with chronic non-cancer pain and opioid-induced constipation. In the first study, 
two doses of ADL5945 (0.10 mg and 0.25 mg) were given twice daily versus placebo to 130 
subjects (43 per treatment arm) over 4 weeks. The second study was of similar design, with 
the exception that only one dose of ADL5945 (0.25 mg) was given and only once daily versus 
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placebo to 80 patients (40 per treatment arm). The primary endpoint in both studies was the 
change from baseline in the mean number of spontaneous bowel movements per week over 
the 4-week treatment period. The results demonstrated a statistically significant and 
clinically relevant effect of the 0.25 mg dose in particular, without tolerability issues and 
evidence of central opioid withdrawal or reversal of opioid analgesia. Adolor’s backup 
compound for opioid-induced constipation is the peripherally-acting mu-opioid-receptor 
antagonist, ADL7745, which recently successfully completed preclinical studies.  
4.3 ALKS37 
ALKS 37 (RDC-1036) is an oral peripherally-acting mu-opioid-receptor antagonist in 
development by Alkermes for the treatment of opioid-induced constipation, with a 
randomized, double-blind, placebo-controlled, multi-dose study recently completed 
(Alkermes website, 2011). The study treated opioid-induced constipation in subjects with 
chronic non-cancer pain with doses of 1 to 100 mg taken once daily. Subjects were eligible to 
participate in the study if they were taking opioid analgesics at doses of 30 mg or more 
morphine equivalents per day and had fewer than three spontaneous bowel movements per 
week.  
The primary endpoint was a change from baseline in the average number of spontaneous 
bowel movements per week. A clear dose-response relationship was demonstrated with a 
statistically significant increase in the average number of spontaneous bowel movements 
per week in the subjects receiving 100 mg of the medication once daily, compared to those 
receiving placebo (4.5 versus 0.7) (p = 0.006). The results also demonstrated a statistically 
significant increase in the average number of complete spontaneous bowel movements per 
week, compared to subjects receiving placebo (3.5 versus 0.8) (p = 0.007). Overall, ALKS 37 
was well tolerated and the most commonly reported adverse events were gastrointestinal in 
nature, including abdominal pain (25%) and diarrhea (22%), mostly occurring in the higher 
and most effective doses (30 mg and 100 mg). There was no indication of reversal of opioid 
analgesia, that is, there was no increase in average daily pain score or opioid use (Alkermes 
Press Release, 2011).    
4.4 NKTR-118 
NKTR-118, also known as PEG-naloxol, is a combination of naloxol, a derivative of the 
opioid antagonist, naloxone, and a polyethylene glycol moiety. The purpose of the 
PEGylation is twofold, that is: 1. altering its metabolism, thereby reducing the first-pass 
effect and increasing its bioavailability, and 2. modifying its distribution to reduce 
penetration into the central nervous system. A randomized, double-blind, placebo-
controlled, multiple-dose study was performed, evaluating the safety and efficacy of NKTR-
118 in subjects with opioid-induced constipation (Webster, L., 2009). Eligible subjects were 
defined as having opioid-induced constipation with fewer than three spontaneous bowel 
movements per week and on a stable analgesic opioid regimen of 30 mg to 1000 mg 
morphine equivalents per day for a minimum of 2 weeks. A total of 208 subjects were 
randomized to NKTR-118 or placebo in three sequential cohorts. The first week they 
received a once daily dose of single-blind placebo, followed by 4 weeks of NKTR-118 once 
daily in doses of 5, 25, or 50 mg, or placebo.  
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The primary endpoint was achieved in both the 25-mg and 50-mg treatment groups, with a 
significant increase in the mean number of spontaneous bowel movements per week over 
the first week. Subjects receiving 25 mg NKTR-118 had an average of 5.0 spontaneous bowel 
movements during the first week (1.4 at baseline) versus 3.1 in the placebo group (1.2 at 
baseline)(p = 0.002). Subjects receiving 50 mg NKTR-118 had an average of 6.0 spontaneous 
bowel movements during the first week (1.6 at baseline) versus 3.3 in the placebo group (1.3 
at baseline)(p = 0.0001). The increase in bowel movements was sustained at a statistically 
significant level throughout the 4 weeks in both dose groups (p = 0.002 and p<0.0001, 
respectively). The medication was well tolerated and adverse events were dose-dependent, 
occurring most frequently in the 50-mg group, and were primarily gastrointestinal in 
nature, particularly abdominal pain, cramps, diarrhea, and nausea. The majority of the 
adverse events were rated as mild or moderate in intensity. Reversal of opioid analgesia was 
not observed in the study, as measured by numerical pain rating and opioid requirement.  
4.5 S-297995 
Shionogi has developed an oral peripherally-acting mu-opioid-receptor antagonist, S-
297995. Initially, it was designed to alleviate a spectrum of opioid-induced side effects 
(constipation, nausea, and vomiting) but the more recent studies have focused primarily on 
its effects on opioid-induced constipation. S-297995 may prove more favorable than existing 
treatments, given its efficacy at lower doses in alleviating not just opioid-induced 
constipation but also nausea and vomiting (Shionogi website, 2011).        
In 2011, a randomized, double-blind, placebo-controlled, single-ascending dose study was 
completed to evaluate the safety and efficacy of S-297995 in opioid-induced constipation. 
Subjects were eligible to participate in the study if they had chronic pain requiring 90 mg or 
more morphine equivalents daily for a minimum of 3 months, opioid-induced constipation, 
and physical opioid dependence. Seventy five subjects were randomized to one of six S-
297995 cohorts (0.01 mg, 0.03 mg, 0.1 mg, 0.3 mg, 1.0 mg, or 3.0 mg). Preliminary results 
demonstrate a statistically significant and dose-dependent increase from baseline in the 
number of spontaneous bowel movements at 24 hours post-dose, starting at doses of 0.3 mg 
(p = 0.0011 in the 0.3-mg group and p<0.001 in both the 1.0-mg and 3.0-mg groups). The 
medication was generally well tolerated with predominantly mild or moderate 
gastrointestinal adverse events. There was no evidence of central opioid withdrawal and 
there was no impact on the analgesic effect of the opioids or a change in pupil size (Shionogi 
Annual Report, 2011).  
4.6 TD-1211 
TD-1211 is a multivalent compound designed by Theravance to block the effects of opioids on 
the gastrointestinal mu-opioid receptors, without mitigating their central analgesic properties. 
In preclinical studies, the medication demonstrated oral bioavailability with no evidence of 
activity in the central nervous system. A randomized, double-blind, placebo-controlled, dose-
escalation study assessed the efficacy and safety of the medication in subjects with non-cancer 
pain and opioid-induced constipation (Theravance Press Release, 2011). The latter was defined 
as fewer than five spontaneous bowel movements during a 2-week baseline period and at least 
one additional symptom of constipation. A total of 70 subjects were randomized to receive oral 
0.25, 0.75, 2.0, 5.0, and 10.0 mg doses of TD 1211 daily, or placebo.  
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The primary endpoint was the change from baseline in the average spontaneous bowel 
movements per week over the 2-week treatment period. Proof of efficacy was achieved in a 
dose-dependent fashion, specifically with the 5 and 10 mg doses. In the subjects who 
received the 5 mg dose, the mean number of spontaneous bowel movements increased by 
3.2 (from 1.1 at baseline to 4.3 over the 2-week treatment period; confidence interval: 1.5-5.0). 
Similarly, in the subjects who received the 10 mg dose, the mean number of spontaneous 
bowel movements increased by 4.9 (from 1.4 at baseline to 6.3 over the 2-week treatment 
period; confidence interval: 3.1-6.7). However, in the placebo-treated group, the increase in 
the mean number of spontaneous bowel movements was not statistically significant (from 
1.7 at baseline to 3.3 over the 2-week treatment period; confidence interval: 0.6-2.5).  
Regarding the median time to first spontaneous bowel movement after the first dose of TD-
1211, a dose-dependent reduction was observed in the subjects receiving the 5 and 10 mg 
doses, with the time reduced to 8.6 and 3.6 hours, respectively, versus 28.7 hours in the 
placebo group. Overall, TD-1211 was well tolerated with the majority of the gastrointestinal 
adverse events mild or moderate in intensity, occurring early in treatment and resolving 
within days. There was no evidence of central opioid withdrawal with the medication or 
reversal of opioid analgesia. 
4.7 Lubiprostone 
Lubiprostone is an activator of the CIC-2 chloride channel, increasing water secretion in the 
lumen of the gastrointestinal tract, approved by the Food and Drug Administration for the 
treatment of chronic constipation and constipation-predominant irritable bowel syndrome 
(IBS). It is in development for opioid-induced constipation and two randomized, double-
blind, placebo-controlled studies with this indication have been completed (Sucampo 
website, 2009). The two studies are identical phase 3 trials in which a total of 875 subjects 
with opioid-induced bowel dysfunction were randomized to 12-week treatment with 
lubiprostone, 24 mcg twice daily. The subjects were taking opioid medications for chronic 
non-cancer pain, including fentanyl, methadone, morphine, and oxycodone, for at least 30 
days prior to screening and continued to take these medications for the duration of the 
study. During the 2-week baseline period before randomization, they were required to have 
fewer than three spontaneous bowel movements per week. The overall adverse-event rate 
for the combined studies was 54.9% for lubiprostone and 51.6% for placebo, with nausea 
being most common (15.0% versus 7.5%), followed by diarrhea (8.5% versus 3.7%).   
The primary endpoint of the studies was the change from baseline in the frequency of 
spontaneous bowel movements at week 8 of treatment, which was met in one of the studies 
(OBD0631) but not in the other (OBD0632). The change from baseline in the frequency of 
spontaneous bowel movements in the first study was from 1.42 to 4.54 for lubiprostone and 
from 1.46 to 3.81 for placebo; in the second study, these changes were from 1.60 to 4.10 for 
lubiprostone and from 1.60 to 3.95 for placebo. An interesting post-hoc sub-analysis 
revealed that subjects taking methadone and randomized to lubiprostone experienced a 
lower increase in the frequency of spontaneous bowel movements than lubiprostone-treated 
subjects on other opioids. Methadone was subsequently found to interfere with the mode of 
action of lubiprostone at the level of the CIC-2 chloride channel. A third randomized, 
double-blind, placebo-controlled study with the exclusion of methadone users is currently 
being conducted.  
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5. Conclusion 
Opioid-induced gastrointestinal dysfunction results predominantly from the effect of 
opioids on the mu-opioid receptors in the gastrointestinal tract. Constipation and nausea are 
its most common symptoms, probably occurring in at least half of the patients treated with 
oral opioids. The constipation in particular is not an uncommon reason for patients to 
discontinue the medication or to take it at a dose that is much lower than required for 
adequate pain relief. In addition, it can further decrease the quality of life in patients whose 
quality of life is generally already significantly impaired by chronic pain. With the exception 
of subcutaneous methylnaltrexone for a subset of patients, there are no medications on the 
market for the general population with opioid-induced constipation. Prospective treatments 
are in developement and will undoubtedly obtain marketing approval from the Food and 
Drug Administration within the next several years. With the emergence of these novel 
medications that specifically target the pathophysiology of OIC, there is hope for patients 
who suffer not only from chronic pain but the adverse effects of their opioid pain 
medication. 
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